Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

In an open label, phase 2 trial, 30 patients with MIBC received chemoradiation (mitomycin C plus capecitabine and 20×2.75 Gy to the bladder) combined with four 3-weekly cycles of nivolumab 3 mg ...

Locally advanced non–small cell lung cancer (NSCLC) constitutes a third of new NSCLC diagnoses worldwide. 1, 2 For patients with unresectable disease, the historical standard treatment was definitive ...

Source Reference: Higgins KA, et al "Concurrent chemoradiation +/- atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology/Alliance LU005" ASTRO 2024; Abstract PL-04.

“Deintensification of chemoradiation treatments for HPV-associated oropharyngeal cancers is of very high interest to patients and researchers, but our study makes clear that these approaches ...

Since 2001, postoperative chemoradiation has been the standard of care for gastric cancer, particularly in North America, based on findings from that year's INT0116 trial.

Of note, when an outcome is not reached in a clinical trial, it means that half of the patients in the trial are alive when this was assessed by researchers. “The AFT-16 trial is the first to our ...

Combination drugs in chemoradiation to reduce mortality from 50% to 30%: Study Steffy Thevar / TNN / Updated: Jul 27, 2024, 12:30 IST AA Follow us ...

Less chemoradiation is possible for some cancer patients by Tessa RoyTessa Roy, University of Michigan Credit: Unsplash/CC0 Public Domain ...

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...

Study: Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Image Credit: Prrrettty/Shutterstock.com Background Cancer and immune cell ...

Approximately 30-40% of patients with cervical cancer develop tumor recurrence following chemoradiation, and currently, residual disease is often detected too late to improve survival rates.